McKesson Corporation

▲ Bull Case

• ◆GLP-1 + Specialty + Oncology compound revenue growth at ~7% ex-International through FY2031, with adjusted operating margin expanding from 1.65% to 1.94% as RxTS/Oncology mix grows, driving 13% Adj. EPS CAGR over five years.
• ◆Mechanical buyback engine sustains ~5% annual share count reduction; $4B+ annual buybacks at $700–$1,100 average prices retire 4–5% of float per year, adding near-guaranteed 4–5% to EPS growth independent of operations.
• ◆Re-rating from ~17x to 20–22x forward P/E as market recognizes US Oncology Network and CoverMyMeds as healthcare-platform assets rather than commodity distribution adjuncts; Ontada data-licensing optionality unmodeled in consensus.

▼ Bear Case

• ◆IRA drug-price negotiation extends to GLP-1 and high-volume specialty drugs in 2027–2029 cycles, compressing MCK's dollar spread per unit by 15–25% on fastest-growing categories, creating $200–500M cumulative EPS headwind through FY2029.
• ◆WBA/ClarusONE JV dissolution following Walgreens financial distress or going-private transaction strips $150–250M in annual generic cost advantage; competitors (CAH via Red Oak with CVS) retain analogous structures, creating relative disadvantage.
• ◆Distribution-multiple anchoring persists — market refuses to award platform multiple regardless of mix shift; MCK compresses to 16x forward P/E (~$580 in bear scenario).

“Central debate is distribution business vs. healthcare infrastructure platform. Sell-side analysts agree on near-term EPS growth (~12–15% through FY2027) and broadly hold Buy rating with consensus target $1,101 (+46%). Disagreement centers on terminal multiple: bulls argue 22–25x as RxTS scales toward software-like economics and Oncology becomes captive-network play (DaVita analog); bears argue distribution will always be distribution with 15–18x structural ceiling. Reverse DCF at $757 reveals market pricing only ~5% perpetual FCF growth—meaningfully below management guidance and consensus profiles, suggesting valuation discipline rather than transformation enthusiasm. Secondary debate is IRA exposure magnitude—whether GLP-1 drugs hit 2027 or 2029 negotiation slate and how much manufacturer price compression flows through to distributor economics.”

• ◆Q4 FY2026 earnings + FY2027 guidance progression (guidance $43.80–$44.60); any mid-year raise consistent with 8/8 beat pattern.
• ◆GLP-1 expansion catalysts: oral semaglutide approval (2026–2027), CMS Medicare obesity coverage decision, biosimilar GLP-1 launches (2027+).
• ◆US Oncology Network physician count reaching 2,500 by FY2027 as publicly trackable platform progress signal.
• ◆Medical-Surgical segment separation (management advancing per FY2027 guidance); structure and timing unlock unmodeled value.
• ◆International divestiture completion (final European wind-down FY2027) simplifies business and supports multiple expansion.

• ◆IRA drug-price negotiation on GLP-1 and oncology biologics (2027–2029 cycles) compressing spreads 15–25% on fastest-growing categories; $200–500M EPS headwind.
• ◆WBA/ClarusONE JV dissolution following Walgreens financial stress; loss of $150–250M annual generic cost advantage versus competitors with analogous structures.
• ◆Rite Aid full liquidation (known but ongoing); ~$10–12B revenue exposure already partially absorbed.
• ◆Multiple compression to distribution average (~16x) driven by sentiment/sector framing rather than operational execution.
• ◆Federal DOJ opioid resurgence (incremental $500M–$2B claim); low probability but tail risk.
• ◆Amazon distribution entry (low near-term probability but long-tail competitive risk over 5–10 years).